Adidas AG-B (02197.HK) will hold a Board of Directors meeting on August 27 to approve its interim results.
Three Blades Biotech-B (02197.HK) announced on August 16th that the board of directors will hold a meeting on August 27th, 2024 to consider and approve the mid-year performance of the company and its subsidiaries as of June 30th, 2024, and to consider the distribution of mid-year dividends (if any).
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Express News | Clover Biopharmaceuticals Ltd: Full Phase Ⅰ Data Readout Is Planned by Year-End 2024
Express News | Clover Biopharmaceuticals: Bivalent Scb-1019 Significantly Boosted Rsv-a and Rsv-B Neutralizing Antibody Titers in Older Adults
Express News | Clover Biopharmaceuticals Ltd: Study Showed Favorable Safety & Reactogenicity Profile Comparable to Saline Placebo
Express News | Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent Rsv Vaccine Candidate Scb-1019 in Older Adults
Adidas Bio-Tech (02197.HK) announced positive preliminary data from Phase I clinical trials of its bivalent RSV candidate vaccine SCB-1019 in elderly groups.
On June 18, Gelon Biotechnology-B (02197.HK) announced that in Phase I clinical trials evaluating the SCB-1019 bivalent RSV PreF-trimer subunit candidate vaccine developed based on Gelon Biotechnology's unique Trimer-Tag (protein trimerization) vaccine technology platform, positive preliminary immunogenicity and safety data were obtained in the elderly group. These preliminary data obtained in the elderly group (aged 60-85) are consistent with the positive data obtained in April this year in the young adult group (aged 18-59) announced by the company.
CLOVER BIO-B: 2023 Annual Report
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Bio-B (02197.HK) Announces Bivalent RSV Vaccine Candidate SCB-1019 Phase I Clinical Trial Receives Positive Preliminary Data
Gelonghui, April 8, 丨 Clover Bio-B (02197.HK) announced that in the phase I clinical trial of the bivalent RSV PreF-trimer subunit vaccine candidate SCB-1019 developed by the evaluation company based on Clover Biotech's unique Trimer-Tag (protein trimerization) vaccine technology platform, the first batch of young adults obtained positive preliminary immunogenicity and safety data. In the phase I clinical trial, the first group of young adults (ages 18-59) received SCB-1019 or saline placebo on day 0 (before vaccination) and day 28 (vaccination), respectively
Clover Bio-B (02197) granted a total of 9.463 million share options under the initial public offering after-sales share option plan
Clover Bio-B (02197) issued an announcement. On April 2, 2024, the company announced after the initial public sale...
Clover Biopharmaceuticals Trims Losses in 2023
Clover Bio-B (02197) released annual results, spent 650 million yuan on R&D, and achieved many important milestones in R&D, production and commercialization
Clover Bio-B (02197) announced results for the year ended December 31, 2023, with revenue of 3925...
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023 ANDPROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLESOF ASSOCIATION
Clover Bio-B (02197.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui March 14 | Clover Bio-B (02197.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to evaluate the payment of the final dividend.
CLOVER BIO-B: DATE OF BOARD MEETING
Hong Kong Stock Concept Tracking | The first and only in China! Nicevir monoclonal antibody was approved in China, and many companies snatched the 10 billion blue ocean (with concept stocks)
On January 2, AstraZeneca and Sanofi jointly announced that the long-acting monoclonal antibody Nirsevimab/nirsevimab (nirsevimab), which was jointly developed by the two companies, was officially approved for marketing by the China Drug Administration to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants.
Clover Biopharmaceuticals Publishes Positive Results From SCB-219M Clinical Trial
Clover Bio-B (02197.HK) announces positive data from phase I clinical trial of SCB-219M, a targeted drug for tumor chemotherapy-related thrombocytopenia (CIT)
Gelonghui, December 29 | Clover Bio-B (02197.HK) announced that positive preliminary safety, efficacy, and pharmacokinetics data were obtained in a phase I clinical trial evaluating a new class of drugs SCB-219M. SCB-219M is an innovative bispecific Fc fusion protein-targeting drug containing a thrombocytopenic receptor agonist (TPO-RA) modeptide produced by CHO cells for thrombocytopenia (“CIT”) induced by chemotherapy in cancer patients. This phase I clinical trial is a multicenter, open, dose climbing and dose amplification study
Changes in Hong Kong stocks | Clover Bio-B (02197) rose nearly 5% to launch phase I clinical trial of RSV vaccine candidate
Clover Bio-B (02197) rose nearly 5%. As of press release, it was up 4.92% to HK$0.64, with a turnover of HK$1,464,200.
No Data